GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NextGen Biomed Ltd (XTAE:NXGN) » Definitions » Degree of Financial Leverage

NextGen Biomed (XTAE:NXGN) Degree of Financial Leverage : 0.37 (As of Jun. 2023)


View and export this data going back to 2000. Start your Free Trial

What is NextGen Biomed Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). NextGen Biomed's Degree of Financial Leverage for the quarter that ended in Jun. 2023 was 0.37. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for NextGen Biomed's Degree of Financial Leverage or its related term are showing as below:

XTAE:NXGN's Degree of Financial Leverage is ranked better than
78.67% of 830 companies
in the Medical Devices & Instruments industry
Industry Median: 0.99 vs XTAE:NXGN: 0.37

NextGen Biomed Degree of Financial Leverage Historical Data

The historical data trend for NextGen Biomed's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextGen Biomed Degree of Financial Leverage Chart

NextGen Biomed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Degree of Financial Leverage
Get a 7-Day Free Trial Premium Member Only 0.79 -13.76 0.70 0.47 2.16

NextGen Biomed Semi-Annual Data
Dec13 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.00 0.47 5.36 2.16 0.37

Competitive Comparison of NextGen Biomed's Degree of Financial Leverage

For the Medical Instruments & Supplies subindustry, NextGen Biomed's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NextGen Biomed's Degree of Financial Leverage Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NextGen Biomed's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where NextGen Biomed's Degree of Financial Leverage falls into.



NextGen Biomed Degree of Financial Leverage Calculation

NextGen Biomed's Degree of Financial Leverage for the quarter that ended in Jun. 2023 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -2.691 (Jun. 2023) / -1.482 (Jun. 2022) - 1 )/( -8.991 (Jun. 2023) / -2.831 (Jun. 2022) - 1 )
=0.8158/2.1759
=0.37***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


NextGen Biomed  (XTAE:NXGN) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


NextGen Biomed Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of NextGen Biomed's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


NextGen Biomed (XTAE:NXGN) Business Description

Traded in Other Exchanges
N/A
Address
Azrieli Center, Round Tower 22nd Floor, Tel Aviv, ISR, 6701101
NextGen Biomed Ltd is pharmaceutical company. It manufactures medical instruments. Its products include pain-free auto-injectors, lancet devices and personal use pain alleviators. It develops and markets medical equipments. Its product line include DPS-101, which is used for treatment for psoriasis. Its other product line include DPS-101 phase II/III is in clinical trial.